ArticleEmerging infectious diseases2020
Case Manifestations and Public Health Response for Outbreak of Meningococcal W Disease, Central Australia, 2017.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Public health management of invasive meningococcal disease outbreaks: worldwide 1973-2018, a systematic review.BMC public health · 2024Pooled it
- Changing Clinical Spectrum of Invasive Meningococcal Disease in France (2014-2025): Impact of Age and Meningococcal Lineage on Atypical Presentations.Microorganisms · 2026Article
- Genomic Surveillance of Invasive Meningococcal Disease During a National MenW Outbreak in Australia, 2017-2018.Open forum infectious diseases · 2024Article
- Impact of Meningococcal ACWY Vaccination Program during 2017-18 Epidemic, Western Australia, Australia.Emerging infectious diseases · 2024Article
- The Diverse Spectrum of Invasive Meningococcal Disease in Pediatric and Adolescent Patients: Narrative Review of Cases and Case Series.Infectious diseases and therapy · 2024Review
- Range of Clinical Manifestations Caused by Invasive Meningococcal Disease Due to Serogroup W: A Systematic Review.Infectious diseases and therapy · 2023Review
- Epidemiology, clinical features and outcome of adults with meningococcal meningitis: a 15-year prospective nationwide cohort study.The Lancet regional health. Europe · 2023Article
- Epidemiology of invasive meningococcal disease in Canada, 2012-2019.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- The epidemiology and outcomes of central nervous system infections in Far North Queensland, tropical Australia; 2000-2019.PloS one · 2022Article
- Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination.Infectious diseases and therapy · 2021Review
- A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global Control.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neisseria meningitidis serogroup W has emerged as an increasingly common cause of invasive meningococcal disease worldwide; the average case-fatality rate is 10%. In 2017, an unprecedented outbreak of serogroup W infection occurred among the Indigenous pediatric population of Central Australia; there were 24 cases over a 5-month period. Among these cases were atypical manifestations, including meningococcal pneumonia, septic arthritis, and conjunctivitis. The outbreak juxtaposed a well-resourced healthcare system against unique challenges related to covering vast distances, a socially disadvantaged population, and a disease process that was rapid and unpredictable. A coordinated clinical and public health response included investigation of and empiric treatment for 649 febrile children, provision of prophylactic antimicrobial drugs for 465 close contacts, and implementation of a quadrivalent meningococcal ACWY conjugate vaccine immunization program. The response contained the outbreak within 6 months; no deaths and only 1 case of major illness were recorded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.